Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

被引：14
作者：
Sekhar R.V. [1 ]
Jahoor F. [1 ]
Pownall H.J. [1 ]
Ballantyne C.M. [1 ]
Balasubramanyam A. [1 ]
机构：
[1] Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Insulin Resistance; Cholesteryl Ester Transfer Protein; Lipodystrophy; Postprandial Lipemia; Intramyocellular Lipid;
D O I：
10.1007/s11883-004-0029-2
中图分类号：
学科分类号：
摘要：
The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：173 / 179
页数：6
相关论文
共 50 条
  • [21] HIV-associated lipodystrophy: from fat injury to premature aging
    Caron-Debarle, Martine
    Lagathu, Claire
    Boccara, Franck
    Vigouroux, Corinne
    Capeau, Jacqueline
    TRENDS IN MOLECULAR MEDICINE, 2010, 16 (05) : 218 - 229
  • [22] What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection
    Tien, PC
    Grunfeld, C
    CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (01) : 27 - 32
  • [23] The HIV-associated lipodystrophy syndrome: Research, results, yet more questions
    Gharakhanian, S
    AIDS, 2001, 15 (02) : 271 - 273
  • [24] Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome
    Feldt T.
    Oette M.
    Kroidl A.
    Goebels K.
    Fritzen R.
    Kambergs J.
    Kappert G.
    Vogt C.
    Wettstein M.
    Häussinger D.
    Infection, 2006, 34 (2) : 55 - 61
  • [25] Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy
    Tien, Phyllis C.
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (12)
  • [26] Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy
    Phyllis C. Tien
    Current Atherosclerosis Reports, 2015, 17
  • [27] Possibilities, limits and particularities of plastic surgery treatment in HIV-associated lipodystrophy
    Dana Jianu
    Anca Streinu-Cercel
    Maria Filipescu
    Ștefan Jianu
    Mihaela Vartic
    Oltjon Cobani
    Adrian Streinu-Cercel
    BMC Infectious Diseases, 14 (Suppl 7)
  • [28] Recombinant Human Growth HormoneRationale for Use in the Treatment of HIV-Associated Lipodystrophy
    Stefano Benedini
    Ileana Terruzzi
    Adriano Lazzarin
    Livio Luzi
    BioDrugs, 2008, 22 : 101 - 112
  • [29] Cardiovascular Complications of HIV-Associated Immune Dysfunction
    Zaaqoq, Akram M.
    Khasawneh, Faisal A.
    Smalligan, Roger D.
    CARDIOLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [30] Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities
    Guaraldi, Giovanni
    Baraboutis, Ioannis G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (03) : 437 - 440
12345